Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Relevance of Coagulation Activation in RIsk Assessment and Stratification in Reference to Patient Important Outcomes for Locally Advanced Breast Cancer: The ARIAS Trial

NCT05806632 is registered in ClinicalTrials.gov with Regina Elena Cancer Institute as lead sponsor.

NCT NCT05806632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05806632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Relevance of Coagulation Activation in RIsk Assessment and Stratification in Reference to Patient Important Outcomes for Locally Advanced Breast Cancer: The ARIAS Trial
Lead sponsor
Regina Elena Cancer Institute
Phase
Observational
Overall status
Unknown status
Start date
January 21, 2020
Completion date
December 31, 2023
Enrollment
108 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

local cancer